# US 10,478,451 B2 · Use of dextran sulfate > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,478,451 B2 - Document ID: US10478451B2 - Status: Granted - Kind: B2 - Application number: 15/748,519 - Filed: 2016-07-15 - Published: 2018-08-09 - Granted: 2019-11-19 - Earliest claimed: 2015-07-30 - Assignees: Tx Medic AB - Applicants: TX Medic AB - Inventors: Lars Bruce; Adam Bruce; Anders Waas - Web page: https://patentgrep.com/patent/US10478451B2 ## CPC - A61K 31/721: Dextrans - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence) - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present embodiments relate to the use of dextran sulfate formulated for systemic administration for treatment, inhibition or prevention of cardiac fibrosis in a subject. ## Claims ### Claim 1 A method of treating cardiac fibrosis in a subject, said method comprising systemically administering dextran sulfate, or a pharmaceutically acceptable salt thereof, to a subject suffering from or having a risk of suffering from cardiac fibrosis. ### Claim 2 (depends on 1) The method according to claim 1, wherein systemically administering comprises systemically administering said dextran sulfate, or said pharmaceutically acceptable salt thereof, to a subject having suffered from myocardial infarction or myocardial ischemia. ### Claim 3 (depends on 1) The method according to claim 1, wherein systemically administering comprises intravenously administrating said dextran sulfate, or said pharmaceutically acceptable salt thereof to said subject. ### Claim 4 (depends on 1) The method according to claim 1, wherein systemically administering comprises subcutaneously administrating said dextran sulfate, or said pharmaceutically acceptable salt thereof to said subject. ### Claim 5 (depends on 1) The method according to claim 1, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average molecular weight equal to or below 10 000 Da. ### Claim 6 The method according to claim to 5, wherein said average molecular weight is within a range of 2000 and 10,000 Da. ### Claim 7 The method according to claim to 6, wherein said average molecular weight is within a range of 3000 and 10,000 Da. ### Claim 8 (depends on 7) The method according to claim 7, wherein said average molecular weight is within a range of 3500 and 9500 Da. ### Claim 9 (depends on 8) The method according to claim 8, wherein said average molecular weight is within a range of 4500 and 7500 Da. ### Claim 10 (depends on 9) The method according to claim 9, wherein said average molecular weight is within a range of 4500 and 5500 Da. ### Claim 11 (depends on 5) The method according to claim 5, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has a number average molecular weight (Mn) as measured by nuclear magnetic resonance (NMR) spectroscopy within an interval of 1850 and 2000 Da. ### Claim 12 (depends on 11) The method according to claim 11, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has on average 5.1 glucose units and an average sulfate number per glucose unit of 2.6 to 2.7. ### Claim 13 (depends on 1) The method according to claim 1, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average sulfur content in a range from 15 to 20%. ### Claim 14 (depends on 13) The method according to claim 13, wherein said average sulfur content is about 17%. ### Claim 15 (depends on 1) The method according to claim 1, wherein systemically administering comprises systemically administering an aqueous injection solution comprising said dextran sulfate, or said pharmaceutically acceptable salt thereof, to said subject. ### Claim 16 (depends on 1) The method according to claim 1, wherein systemically administering comprises systemically administering said dextran sulfate, or said pharmaceutically acceptable salt thereof, at multiple times a week for multiple consecutive weeks to said subject. ### Claim 17 (depends on 16) The method according to claim 16, wherein systemically administering comprises systemically administering said dextran sulfate, or said pharmaceutically acceptable salt thereof, at 3 times a week for 3 consecutive weeks to said subject. ### Claim 18 (depends on 1) The method according to claim 1, wherein systemically administering comprises systemically administering said dextran sulfate, or said pharmaceutically acceptable salt thereof, at a dosage in a range from 0.05 to 50 mg/kg of body weight of said subject. ### Claim 19 (depends on 18) The method according to claim 18, wherein systemically administering comprises systemically administering said dextran sulfate, or said pharmaceutically acceptable salt thereof, at a dosage in a range from 0.05 to 30 mg/kg of body weight of said subject. ### Claim 20 (depends on 19) The method according to claim 19, wherein systemically administering comprises systemically administering said dextran sulfate, or said pharmaceutically acceptable salt thereof, at a dosage in a range from 0.1 to 15 mg/kg body weight of said subject. ### Claim 21 (depends on 20) The method according to claim 20, wherein systemically administering comprises systemically administering said dextran sulfate, or said pharmaceutically acceptable salt thereof, at a dosage in a range from 0.1 to 10 mg/kg body weight of said subject. ### Claim 22 (depends on 1) The method according to claim 1, wherein said subject is suffering from a disease or disorder selected from a group consisting of endomyocardial fibrosis, fibrosis following myocardial infarction and atrial fibrosis. ### Claim 23 (depends on 1) The method according to claim 1, wherein systemically administering comprises systemically administering said dextran sulfate, or said pharmaceutically acceptable salt thereof, to said subject for treating interstitial fibrosis in an infarct area of a heart of said subject. ### Claim 24 (depends on 1) The method according to claim 1, wherein said pharmaceutically acceptable salt thereof is a sodium salt of dextran sulfate.